925940-95-0

Basic information

• Product Name: 5-(3-chlorophenyl)isoxazole-3-carboxylic acid
• Synonyms: 5-(3-chlorophenyl)isoxazole-3-carboxylic acid
• CAS NO: 925940-95-0
• Molecular Formula: C₁₀H₆ClNO₃
• Molecular Weight: 223.61
• Mol File: 925940-95-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(3-chlorophenyl)isoxazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-chlorophenyl)isoxazole-3-carboxylic acid(925940-95-0)
• EPA Substance Registry System: 5-(3-chlorophenyl)isoxazole-3-carboxylic acid(925940-95-0)

Safety Data

• Hazardous Substances Data: 925940-95-0(Hazardous Substances Data)

Upstream product

• 657424-79-8 [5-(3-Chloro-phenyl)-isoxazol-3-yl]-methanol 
• 99-02-5 3'-Chloroacetophenone 
• 657424-77-6 ethyl 5-(3-chlorophenyl)isoxazole-3-carboxylate 
• 57961-48-5 ethyl 4-(3-chlorophenyl)-2,4-dioxobutanoate 

Downstream Products

• 1147118-11-3 5-(3-Chlorophenyl)-N-methyl-N-[4-methyl-5-(6-oxo-1,6-dihydropyridazin-4-yl)-4H-1,2,4-triazol-3-yl]isoxazole-3-carboxamide 
• 1147118-09-9 5-(3-Chlorophenyl)-N-methyl-N-(4-methyl-5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)isoxazole-3-carboxamide 

Relevant articles and documents

Design and synthesis of novel 5-arylisoxazole-1,3,4-thiadiazole hybrids as α-glucosidase inhibitors

Background: α-Glucosidase inhibitors have occupied a significant position in the treatment of type 2 diabetes. In this respect, the development of novel and efficient non-sugar-based inhibitors is in high demand. Objective: Design and synthesis of new 5-arylisoxazole-1,3,4-thiadiazole hybrids possessing α-glucosidase inhibitory activity were developed. Methods: Different derivatives were synthesized by the reaction of various 5-arylisoxazole-3-carboxylic acids and ethyl 2-((5-amino-1,3,4-thiadiazol-2-yl)thio)acetate. Finally, they were evalu-ated for their α-glucosidase inhibitory activity. Results: It was found that ethyl 2-((5-(5-(2-chlorophenyl)isoxazole-3-carboxamido)-1,3,4-thiadiazol-2-yl)thio)acetate (5j) was the most potent compound (IC50 = 180.1 μM) compared with acarbose as the reference drug (IC50 = 750.0 μM). Also, the kinetic study of 5j revealed a competitive inhibition and docking study results indicated desired interactions of that compound with amino acid residues located close to the active site of α-glucosidase. Conclusion: Good α-glucosidase inhibitory activity obtained by the title compounds introduced them as an efficient scaffold, which merits to be considered in anti-diabetic drug discovery developments.

Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease

A novel series of hybrid arylisoxazole-chromenone carboxamides were designed, synthesized, and evaluated for their cholinesterase (ChE) inhibitory activity based on the modified Ellman's method. Among synthesized compounds, 5-(3-nitrophenyl)-N-{4-[(2-oxo-

Substituted piperazines as metabotropic glutamate receptor antagonists

The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, Ar2, Hy, L, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.